.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Simon Page

Speaker

15/12/2022
11:45 – 11:50 5 Min.
ePoster Presentation
P 355
AbobotulinumtoxinA efficacy and safety in children with upper limb spasticity previously treated with botulinum toxin
Pediatric neurorehabilitation, Spasticity

Further involvements

15/12/2022
11:45 – 11:50 5 Min.
ePoster Presentation
P 355
AbobotulinumtoxinA efficacy and safety in children with upper limb spasticity previously treated with botulinum toxin
Pediatric neurorehabilitation, Spasticity
16/12/2022
15:30 – 15:35 5 Min.
ePoster Presentation
P 097
Which are the most frequently injected muscles in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in routine practice? Baseline data from the AboLiSh study
Motor neurorehabilitation, Spasticity
16/12/2022
15:45 – 15:50 5 Min.
ePoster Presentation
P 389
The detrimental impact of the COVID-19 pandemic on the management of post-stroke spasticity in England
COVID-19/SARS-CoV-2-related problems, Public health issues and health politics